B. Riley upped their FY2025 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a report issued on ...

CEO Christopher Richard Anzalone sold 11,520 shares of the stock in a transaction that occurred on Thursday, January 2nd. The ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter ...

PASADENA, Calif.—Hamilton James C, Chief of Discovery/Trans Medicine at Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biotechnology company currently valued at $2.45 billion, sold a ...

Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on X4 Pharmaceuticals (XFOR – Research Report) today and set a price target of ...

Don’t be jinxing that,” Chiefs offensive coordinator Matt Nagy said with a smile when asked about this crucial change.